bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
December 01 2022 - 8:00AM
Business Wire
bioAffinity reports on a potential therapeutic
approach that kills cancer cells without harm to normal cells
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a
biotechnology company addressing the need for noninvasive diagnosis
of early-stage cancer and diseases of the lung and targeted cancer
treatment, today announced that David Elzi, Ph.D., bioAffinity Vice
President of Research, will discuss his research into a possible
mechanism by which the knock down of two genes kills cancer cells
with little or no effect on normal cells at Cell Bio, a joint
meeting of the American Society for Cell Biology (ASCB) and
European Molecular Biology Organization (EMBO), in Washington,
D.C., on Dec. 3-7, 2022. Dr. Elzi’s research supports the Company’s
development of broad-spectrum cancer therapeutics.
Dr. Elzi will present a poster titled “Reassessing Cobalamin
Requirements in Cell Culture” on Monday, Dec. 5, 2022, from 12:15
p.m. to 1:45 p.m. EST at the Walter E. Reed Convention Center in
Washington, D.C.
“bioAffinity’s research is important in better understanding the
foundation of our therapeutic platforms as it examines one
potential mechanism for how silencing the genes CD320 and LRP2
together kills cancer cells but leaves normal cells unharmed,” Dr.
Elzi said.
“We previously reported on the Company’s design and use of
siRNAs to kill multiple cancers at the cellular level, including
prostate, lung, breast, brain and skin cancers, without harm to
normal cells,” said bioAffinity President and CEO Maria Zannes. “We
have reported on how to deliver the potential therapy. Dr.
Elzi’s recent research that will be presented next week at Cell Bio
looks at why it works.”
Cell Bio 2022, the joint meeting of the ASCB and EMBO, will
showcase a diverse global community of the brightest minds in cell
biology in person, Dec. 3-7, 2022, in Washington, D.C. The unique
meeting focuses on cell biology as the fundamental basis of biology
as well as sessions on emerging interdisciplinary topics.
About bioAffinity Technologies,
Inc.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses
the need for noninvasive diagnosis of early-stage cancer and
diseases of the lung, and targeted cancer treatment. The Company’s
first product, CyPath® Lung, is a non-invasive test that has shown
high sensitivity and specificity for the detection of early-stage
lung cancer. Precision Pathology Services licensed and developed
CyPath® Lung as a Laboratory Developed Test (LDT) and has begun
test marketing in Texas. OncoSelect® Therapeutics, LLC, a
subsidiary of bioAffinity Technologies, is advancing its
discoveries shown in vitro to kill cancer cells without harm to
normal cells. Research and optimization of the Company’s platform
technologies are conducted in its laboratories at The University of
Texas at San Antonio.
Forward-Looking
Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221201005338/en/
Company Contact: Maria Zannes, President & Chief
Executive Officer mz@bioaffinitytech.com
Investor Relations Contact: Tiberend Strategic Advisors,
Inc. Jonathan Nugent jnugent@tiberend.com or David Irish
dirish@tiberend.com
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Mar 2024 to Apr 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Apr 2023 to Apr 2024